Mumbai-based Ipca Laboratories and Bhami’s Research Laboratory (BRL) have entered into a definitive global licensing agreement that grants Ipca access to BRL's proprietary high-concentration subcutaneous biologics delivery platform.

Under the agreement, BRL will undertake proof-of-concept and formulation development activities, while Ipca will be responsible for further research and development, clinical trials, commercial manufacturing and product launches.

The licensing arrangement covers worldwide rights. BRL will receive a defined milestone fee related to the technology transfer and will also earn royalties on net sales upon commercialisation of the products.

Commenting on the partnership, Pranay Godha, Managing Director and Chief Executive Officer of Ipca Laboratories, said the collaboration combines Ipca's scientific capabilities with BRL's formulation platform to accelerate the development of affordable biologics for patients battling cancer and autoimmune diseases globally.

BRL Co-founder and Chief Executive Officer Dr Suryakanth M Pai said the partnership would expand the reach of the company's proprietary and patented subcutaneous protein delivery platform technology and help develop differentiated biologics for global markets. He added that the collaboration is aimed at making patient care more convenient, affordable and safe.

Akhil Shah, Director and Chief Executive Officer of WeTranslate, said BRL has built a differentiated formulation technology platform, while Ipca brings the scale, expertise and global reach required for commercialisation. He added that WeTranslate was pleased to support the collaboration and its potential impact on biologic drug delivery.

Source: CNBC TV

The collaboration will focus on the development and commercialisation of multiple monoclonal antibody products targeting oncology and inflammatory diseases.